Scinai Immunotherapeutics (SCNI) Income from Continuing Operations (2014 - 2026)
Scinai Immunotherapeutics (SCNI) posted Income from Continuing Operations of 2467000.0 for Q1 2026, down 12.39% sequentially from 2195000.0 in Q2 2025, and down 57.33% YoY from 5782146.49 in Q1 2025.
Scinai Immunotherapeutics (SCNI) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Scinai Immunotherapeutics has reported Income from Continuing Operations for 13 years, with the latest figure at 2467000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 57.33% year-over-year to 2467000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 9866000.0 (down 1461.08% YoY) and the FY2025 annual result came in at 38262000.0, down 18.32% from the prior year.
- Income from Continuing Operations eased to 2467000.0 in Q1 2026 per SCNI's latest filing, from 2195000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 10455000.0 in Q3 2024 and troughed at 22550000.0 in Q4 2022.
- A 5-year average of 1441466.67 and a median of 1878000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations tumbled 614.25% in 2022, then jumped 259.86% in 2024.
- Over 5 years, Income from Continuing Operations stood at 22550000.0 in 2022, then soared by 75.01% to 5635000.0 in 2023, then surged by 35.47% to 3636000.0 in 2024, then surged by 39.63% to 2195000.0 in 2025, then slipped by 12.39% to 2467000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 2467000.0, 2195000.0, and 1568000.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Scinai Immunotherapeutics | 11.72 Mn | -3.10 Bn | -1.12 Mn | -2.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.47 Mn |
| Jun 30, 2025 | -2.20 Mn |
| Mar 31, 2025 | -1.57 Mn |
| Dec 31, 2024 | -3.64 Mn |
| Sep 30, 2024 | 10.46 Mn |
| Jun 30, 2024 | -5.88 Mn |
| Mar 31, 2024 | 1.79 Mn |
| Dec 31, 2023 | -5.64 Mn |
| Sep 30, 2023 | -6.54 Mn |
| Jun 30, 2023 | 1.82 Mn |
| Mar 31, 2023 | 2.46 Mn |
| Dec 31, 2022 | -22.55 Mn |
| Sep 30, 2022 | 7.30 Mn |
| Jun 30, 2022 | 6.91 Mn |
| Mar 31, 2022 | -1.88 Mn |
| Dec 31, 2021 | 4.39 Mn |
| Sep 30, 2021 | -5.42 Mn |
| Jun 30, 2021 | -5.81 Mn |
| Mar 31, 2021 | -1.24 Mn |
| Dec 31, 2020 | -15.31 Mn |